Sharing Compounds for Leishmaniasis Drug Discovery
Leishmania is a parasite that disfigures or kills two million people every year in the developing world. There may be concerns about the efficacy and safety of current antileishmanial agents. In order to address this high-priority gap, Dr. Dawn Wetzel, Assistant Professor of Pediatrics and Pharmacology at UTSW, has identified a specific class of inhibitors with biological activity against Leishmania parasites. In order to support Dr. Wetzel’s antiparasitic screening efforts, Eisai Co., Ltd., has agreed to share inhibitors from this class of compounds.